Zacks Investment Research upgraded shares of Kura Oncology, Inc. (NASDAQ:KURA) from a hold rating to a buy rating in a research report sent to investors on Friday. They currently have $15.00 price objective on the stock.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
Other analysts have also recently issued reports about the company. Citigroup Inc. set a $13.00 price objective on Kura Oncology and gave the company a buy rating in a research note on Tuesday, August 8th. Oppenheimer Holdings, Inc. reiterated a buy rating and issued a $16.00 price objective on shares of Kura Oncology in a research note on Tuesday, July 4th. Leerink Swann reiterated an outperform rating and issued a $18.00 price objective (up from $16.00) on shares of Kura Oncology in a research note on Thursday, August 10th. ValuEngine upgraded Kura Oncology from a sell rating to a hold rating in a research note on Friday, September 8th. Finally, Cowen and Company began coverage on Kura Oncology in a research note on Thursday, September 7th. They issued an outperform rating on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $15.60.
Kura Oncology (KURA) opened at 12.85 on Friday. Kura Oncology has a 52-week low of $4.00 and a 52-week high of $13.80. The company’s market capitalization is $256.85 million. The stock has a 50 day moving average price of $8.46 and a 200 day moving average price of $8.93.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Monday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.03. On average, equities analysts expect that Kura Oncology will post ($1.53) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Kura Oncology, Inc. (KURA) Raised to “Buy” at Zacks Investment Research” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.chaffeybreeze.com/2017/09/19/kura-oncology-inc-kura-raised-to-buy-at-zacks-investment-research.html.
Several hedge funds and other institutional investors have recently made changes to their positions in KURA. Morgan Stanley raised its stake in shares of Kura Oncology by 175.5% in the first quarter. Morgan Stanley now owns 430,428 shares of the company’s stock valued at $3,788,000 after acquiring an additional 274,166 shares in the last quarter. State Street Corp acquired a new stake in shares of Kura Oncology in the second quarter valued at $1,394,000. Northern Trust Corp raised its stake in Kura Oncology by 939.3% in the second quarter. Northern Trust Corp now owns 147,483 shares of the company’s stock valued at $1,372,000 after buying an additional 133,293 shares in the last quarter. Alethea Capital Management LLC raised its stake in Kura Oncology by 128.1% in the second quarter. Alethea Capital Management LLC now owns 193,346 shares of the company’s stock valued at $1,798,000 after buying an additional 108,577 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in Kura Oncology in the first quarter valued at $533,000. Institutional investors and hedge funds own 39.07% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.